CPA Submits Section 232 Comments on Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices

CPA Submits Section 232 Comments on Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices

The Trump administration’s section 232 investigation into medical devices and personal protective equipment is a vital step toward ensuring America takes back control over its production and domestic supply of critical medical products.

ICYMI: CPA Economist Andrew Rechenberg Stars at Hearing on Fixing America’s Broken Drug Supply Chain

ICYMI: CPA Economist Andrew Rechenberg Stars at Hearing on Fixing America’s Broken Drug Supply Chain

The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.

CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry

CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry

CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.

CPA Calls on Trump Administration to Take Strong, Decisive Action to Decouple from China and Strengthen U.S. Industrial Capacity

CPA Calls on Trump Administration to Take Strong, Decisive Action to Decouple from China and Strengthen U.S. Industrial Capacity

The era of global dependency on the CCP is over. For decades, Wall Street, multinational corporations, and globalist institutions helped finance China’s rise at the direct expense of American workers, manufacturers, and national security.

CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis

CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis

CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.

Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production

Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production

The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.